Related Experiment Video
Updated: May 28, 2025
Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
Published on: December 27, 2017
Refractory immune thrombocytopenia treated with low-dose decitabine combined with recombinant human thrombopoietin or
Yuxia Jiang1, Yani Xu2, Haiying Wu1
1Department of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, P.R. China.
Rationale:
Immune thrombocytopenia (ITP) is an autoimmune-mediated disorder caused by antibody-mediated platelet destruction and impaired platelet production by megakaryocytes. Treating refractory ITP remains a significant challenge.
Patient Concerns And Diagnoses:
We report 2 patients with refractory ITP.
Interventions And Outcomes:
Two patients received low-dose decitabine combined with recombinant human thrombopoietin or eltrombopag. Platelet counts in both patients increased to within the normal range.
Lessons:
Low-dose decitabine combined with recombinant human thrombopoietin or eltrombopag may exert a synergistic effect in the treatment of refractory ITP.
